Company expects current cash position will fund operations into mid-2027
Overview
U.S. biotech firm's Q2 net loss widened yr/yr as R&D expenses increased
Company ended Q2 with $225 mln in cash after May 2026 capital raise
Company expects cash to fund operations into mid-2027
Result Drivers
Increased R&D spending - Higher research and development expenses driven by advancement of rese-cel clinical trials across multiple autoimmune indications
Manufacturing partnerships - Expanded manufacturing agreements to support anticipated scale and supply chain resiliency for rese-cel
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
$0.34
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
CABA•
